Press Releases Nykode Therapeutics

Equities

VACC

NO0010714785

Real-time Oslo Bors Other stock markets 08:24:32 2024-07-03 am EDT			5-day change	1st Jan Change
13.93 ^NOK	-4.65%		-5.69%	-34.91%

Jun. 20	Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting	CI
Jun. 11	Nykode Therapeutics ASA Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Nykode Therapeutics : Grant of share options	Jul. 01	PU
Nykode Therapeutics : Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting	Jun. 20	PU
Nykode Therapeutics : presentation from ABGSC Seminar on Autoimmunity, Transplantation & Inflammation	Jun. 11	PU
Nykode Therapeutics : Q1 2024 Financial Results – presentation	May. 14	PU
Nykode Therapeutics : Q1 2024 Financial Results	May. 14	PU
Nykode Therapeutics : reports Q1 2024 Financial Results	May. 14	PU
Nykode Therapeutics : Remuneration Report 2023	Apr. 19	PU
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider	23-10-27	AQ
Nykode Therapeutics : 2Q 2023 Financial Results – presentation	23-08-23	PU
Nykode Therapeutics : ABGSC Life Science Summit 30-31 May 2023 – presentation	23-06-07	PU
Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the next trial in Advanced Cervical Cancer	23-06-01	GL
Nykode Therapeutics to Present at Jefferies Healthcare Conference	23-05-30	GL
Nykode Therapeutics : 1Q 2023 Financial Results – presentation	23-05-12	PU
Nykode Therapeutics : Nomination Committee Proposal	23-04-20	PU
Nykode Therapeutics : Final Results from the Phase 2 VB-C-02 trial – presentation	23-04-19	PU
Nykode Therapeutics : ESG Report 2022	23-04-19	PU
Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer	23-04-18	GL
Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer	23-04-18	AQ
Nykode Therapeutics : Remuneration Guidelines	23-04-13	PU
Nykode Therapeutics : 4Q 2022 Financial Results – presentation	23-02-28	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Nykode Therapeutics

Equities

VACC

NO0010714785

Press Releases

Filters